Houwerzijl Ewout J, Louwes Henk, Sluiter Wim J, Smit Jan W, Vellenga Edo, de Wolf Joost Th M
Department of Hematology, University Medical Center Groningen, PO Box 30001, 9700 RB, and Department of Nuclear Medicine, Martin Hospital Groningen, Groningen, The Netherlands.
Ann Hematol. 2008 Dec;87(12):975-83. doi: 10.1007/s00277-008-0537-1. Epub 2008 Aug 9.
The predictive value of clinical and platelet kinetic parameters for treatment outcome in idiopathic thrombocytopenic purpura (ITP) was investigated in 75 patients with platelets<or=20x10(9)/L. The platelet kinetic studies showed that the platelet production rate (PPR) was decreased (<100x10(9)/day), normal, or increased (>355x10(9)/day) in 33%, 48%, and 19% of patients, respectively. All patients started with prednisone at diagnosis (1 mg/kg/day). Initial complete and partial response (CR/PR) rate was 84% and a durable CR/PR (>or=6 months without treatment) was attained in 44% of the patients. Durable CR/PR was noticed in 64% of the patients with decreased PPR during a median follow-up time without treatment of 81 (range 18-92) months, compared to 34% of the patients with normal or increased PPR during a median follow-up time without treatment of 141 (range 10-284) months (p=0.03). Splenectomy was performed in 32% of patients with decreased PPR and in 62% of patients with normal or increased PPR (p=0.03). In conclusion, ITP patients with suppressed PPR have a significant higher durable CR/PR rate to prednisone therapy and are less frequently exposed to splenectomy than those with a normal or increased PPR.
对75例血小板计数≤20×10⁹/L的特发性血小板减少性紫癜(ITP)患者,研究了临床和血小板动力学参数对治疗结果的预测价值。血小板动力学研究显示,分别有33%、48%和19%的患者血小板生成率(PPR)降低(<100×10⁹/天)、正常或升高(>355×10⁹/天)。所有患者诊断时均开始使用泼尼松(1mg/kg/天)。初始完全缓解和部分缓解(CR/PR)率为84%,44%的患者获得持久CR/PR(≥6个月未治疗)。在中位未治疗随访时间81个月(范围18 - 92个月)时,PPR降低的患者中有64%出现持久CR/PR,而PPR正常或升高的患者在中位未治疗随访时间141个月(范围10 - 284个月)时,这一比例为34%(p = 0.03)。PPR降低的患者中有32%接受了脾切除术,PPR正常或升高的患者中有62%接受了脾切除术(p = 0.03)。总之,与PPR正常或升高的ITP患者相比,PPR受抑制的ITP患者对泼尼松治疗的持久CR/PR率显著更高,且接受脾切除术的频率更低。